Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3613226 | 0.89 | KDM4E (0.74) | KDM4EALDH1A1MAPTHSD11B1L3MBTL1 | |
| SCHEMBL31061396 | 0.81 | KDM4E (0.66) | KDM4EALDH1A1MAPTHSD11B1L3MBTL1 | |
| SCHEMBL3219201 | 0.78 | MAPT (0.50) | KDM4EALDH1A1MAPTHSD11B1 | |
| SCHEMBL31061364 | 0.78 | KDM4E (0.63) | KDM4EALDH1A1MAPTHSD11B1L3MBTL1 | |
| SCHEMBL3608843 | 0.78 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL3600596 | 0.78 | KDM4E (1.00) | KDM4EALDH1A1HSD11B1L3MBTL1KMT2A | |
| SCHEMBL4402433 | 0.76 | LMNA (0.90) | ALDH1A1HSD11B1KMT2AMEN1TDP1 | |
| SCHEMBL31061461 | 0.76 | KDM4E (0.60) | KDM4EALDH1A1MAPTHSD11B1L3MBTL1 | |
| SCHEMBL31061030 | 0.76 | KDM4E (0.60) | KDM4EALDH1A1MAPTHSD11B1L3MBTL1 | |
| SCHEMBL31061414 | 0.75 | ALDH1A1 (0.67) | KDM4EALDH1A1MAPTHSD11B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | claimed |
| US-7825122-B2 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825122-B2 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825122-B2 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | disclosed |
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | disclosed |
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | GLP1R, GPR119, INSR | KDM4E 2658/4885ALDH1A1 469/4885MAPT 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.